Mizuho Securities

Founded in 1968, Intel designs, manufactures, and sells essential technologies for cloud, smart, and connected devices worldwide. Its product portfolio includes platform products like central processing units and chipsets, along with non-platform products such as accelerators, boards and systems, connectivity products, and memory and storage products. Intel serves original equipment manufacturers, original design manufacturers, and cloud service providers.

Plus Power is a company focused on the development, ownership, and operation of independent battery energy storage systems. Its technology is designed to enhance the flexibility of the electrical grid by providing capacity, energy, and ancillary services. By enabling the swift integration of renewable energy sources, Plus Power helps manage fluctuations in power generation by storing excess energy and reinjecting it into the grid when demand arises. This approach allows for a more efficient and reliable energy system, facilitating the transition toward a renewable energy landscape.

Suono Bio, Inc. is a biotechnology company based in Medford, Massachusetts, that focuses on designing and developing innovative therapeutic products with a unique delivery technology. Established in 2016, the company specializes in enabling ultra-rapid, localized delivery of small molecules, biologics, nucleic acids, and gene therapies directly to the gastrointestinal tract without the need for encapsulation. Suono Bio aims to transform the treatment landscape for difficult-to-treat diseases, particularly those mediated by inflammatory processes, by facilitating effective therapy delivery that enhances patient recovery from gastrointestinal conditions.

One Tap BUY Co., Ltd., founded in 2013 and based in Tokyo, Japan, specializes in developing finance-related application services, particularly in asset management. The company offers a financial smartphone application known as my banker, which enables users to select, buy, and sell stocks with smaller investment amounts. The application facilitates trading throughout the day, allowing users to manage their investments by buying and selling only the profits while retaining ownership of the stocks. Originally established as My banker Co., Ltd., the company rebranded to One Tap BUY in January 2015 to reflect its focus on simplifying the investment process for individual users.

PayPay is a mobile payment application that enables users to make secure and convenient payments. It has a per-person granting limit of 15,000 yen for a single payment and 30,000 yen for the total monthly limit.

HiJoJo Partners, Inc. is a venture capital firm established in 2017 and based in Minato, Japan. The company specializes in providing investment opportunities in high-quality middle and late-stage private companies, including unicorns, both domestically and internationally. HiJoJo Partners focuses on direct investments in pre-IPO shares through various financing rounds and secondary markets, catering to the interests of domestic investors seeking access to global large-cap private companies.

One Tap BUY Co., Ltd., founded in 2013 and based in Tokyo, Japan, specializes in developing finance-related application services, particularly in asset management. The company offers a financial smartphone application known as my banker, which enables users to select, buy, and sell stocks with smaller investment amounts. The application facilitates trading throughout the day, allowing users to manage their investments by buying and selling only the profits while retaining ownership of the stocks. Originally established as My banker Co., Ltd., the company rebranded to One Tap BUY in January 2015 to reflect its focus on simplifying the investment process for individual users.

Visco Technologies is a manufacturing company based in Tokyo, Japan, that develops, manufactures, sells, and maintains machine vision and image processing systems and services. It provides visual inspection algorithms and image processing technology, including alignment, checking, measuring, recognition, and existence checks, to help manufacturers and industrial operators improve precision, efficiency, and reliability in their operations.

PayPay is a mobile payment application that enables users to make secure and convenient payments. It has a per-person granting limit of 15,000 yen for a single payment and 30,000 yen for the total monthly limit.

One Tap BUY Co., Ltd., founded in 2013 and based in Tokyo, Japan, specializes in developing finance-related application services, particularly in asset management. The company offers a financial smartphone application known as my banker, which enables users to select, buy, and sell stocks with smaller investment amounts. The application facilitates trading throughout the day, allowing users to manage their investments by buying and selling only the profits while retaining ownership of the stocks. Originally established as My banker Co., Ltd., the company rebranded to One Tap BUY in January 2015 to reflect its focus on simplifying the investment process for individual users.

One Tap BUY Co., Ltd., founded in 2013 and based in Tokyo, Japan, specializes in developing finance-related application services, particularly in asset management. The company offers a financial smartphone application known as my banker, which enables users to select, buy, and sell stocks with smaller investment amounts. The application facilitates trading throughout the day, allowing users to manage their investments by buying and selling only the profits while retaining ownership of the stocks. Originally established as My banker Co., Ltd., the company rebranded to One Tap BUY in January 2015 to reflect its focus on simplifying the investment process for individual users.

PayPay is a mobile payment application that enables users to make secure and convenient payments. It has a per-person granting limit of 15,000 yen for a single payment and 30,000 yen for the total monthly limit.

SE Holdings and Incubations Co., Ltd. is a Japan-based holding company that operates across various business segments. Its Publishing segment focuses on publishing and selling general and computer-related books, providing technical information online, and offering educational conferences. The Corporate Services segment supports product marketing, user assistance, public relations, and investor relations. In the Software Network segment, the company develops and sells entertainment software, offers Internet technologies, maintains cellular phone services, and operates amusement facilities. The Internet Cafe segment manages Internet cafes, while the Education and Personnel segment provides manpower dispatching services. Additionally, the Others segment oversees real estate properties, contributing to the company's diverse portfolio.

Perlegen Sciences engages in the discovery and commercialization of genetic variations that provide physicians with information to improve the clinical decision-making process and patient treatment outcomes. Its products include MammaPLUS, a breast cancer risk stratifier and a panel of common genetic variants that stratifies individual genetic and background/clinical risk for those at moderately elevated risk for non-familial breast cancer, as well as impacts the risk for developing invasive breast cancer; and Genotype Browser Website that provides a way to access and view the results of a study of genetic variation in various diverse human populations. Perlegen Sciences, Inc. was founded in 2000 and is based in Mountain View, California.

SMS is a Japanese company focused on providing information services tailored to the needs of an aging society. The company operates in multiple sectors, including nursing care, medical care, career development, healthcare, senior living, and international services. By catering to both business operators and end users, SMS aims to enhance the information infrastructure necessary for supporting the elderly and those involved in their care. Through its diverse offerings, SMS addresses the unique challenges and requirements of an aging population, facilitating access to essential services and information.

Perlegen Sciences engages in the discovery and commercialization of genetic variations that provide physicians with information to improve the clinical decision-making process and patient treatment outcomes. Its products include MammaPLUS, a breast cancer risk stratifier and a panel of common genetic variants that stratifies individual genetic and background/clinical risk for those at moderately elevated risk for non-familial breast cancer, as well as impacts the risk for developing invasive breast cancer; and Genotype Browser Website that provides a way to access and view the results of a study of genetic variation in various diverse human populations. Perlegen Sciences, Inc. was founded in 2000 and is based in Mountain View, California.

SourceNext is a company that specializes in the planning, development, and sales of personal computer software, along with utility software and training products. The firm employs a variety of software development methods, including in-house development and outsourcing, as well as acquiring licenses from other companies for commercialization. SourceNext markets its products through multiple channels, including mobile phone operators, its own online stores, and wholesale distribution to home appliance discount stores and various electronic commerce websites.

MediciNova is a biopharmaceutical company focused on acquiring and developing small-molecule therapeutics for diseases with unmet medical needs, with emphasis on the United States market. Its diverse pipeline includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for neurological disorders; MN-221 (bedoradrine) for acute asthma exacerbations; MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin-binding agent for solid tumors. The company pursues collaborations and alliances to advance its portfolio, including vaccine development efforts with BioComo and Mie University and partnerships with Japanese pharmaceutical companies. Development efforts focus on neurology, fibrosis, and oncology, aiming to address medical needs through clinical and preclinical programs.